CollPlant Biotechnologies Ltd.

Greetings and welcome to the Coal Plant Biotechnology's third quarter 2024 earnings call. At this time, all participants are in a listen-only mode. The question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce Dori Kurowski with Lifestyle Advisors. Thank you. You may begin.

I would like to welcome everyone. to Coal Plant Biotechnology's Financial Results Conference call to discuss the results for the third quarter ended September 30th, 2024, where management will also provide a corporate business update. With us on the call today from Coal Plant are Ihil Tal, Chief Executive Officer, who will provide an overview of the company's programs and associated updates, and Aran Rotem, Deputy CEO and Chief Financial Officer. who will provide a summary of Coal Plant's financial results for the second quarter ending September 30th, 2024. Both will be able to answer questions at the end of the call. Before we get started, I would like to remind everyone that statements made on this conference call may include forward-looking statements. Actual events or results could differ materially from those expressed or implied by any forward-looking statements as a result of various risk uncertainties, and other factors, including those set forth in the Risk Factors section of Coal Plant's filings with the Securities and Exchange Commission. These filings can be found at www.sec.gov or on Coal Plant's website at www.coalplant.com. In addition, any forward-looking statements made on this call represent Coal Plant's views only as of today, November 27, 2024, and should not be relied upon as representing the company's views as of any subsequent date. Coal plant management specifically disclaims any obligation to update or revise any of these forward-looking statements. Finally, coal plant management will refer to certain financial measures not reported in accordance with GAAP on this call. You can find reconciliations of these non-GAAP financial measures to the GAAP financial measures in the earnings press release that Coal Plant published earlier today, and which is available on Coal Plant's website at ir.coalplant.com. Now let me turn the call over to Yihil Tao, Chief Executive Officer of Coal Plant Biotechnologies. Please go ahead, sir.

Good morning, everyone, and thank you for joining us today on Coal Plant's investor conference call to discuss our third quarter 2024 financial results and corporate development as we pursue our mission to be a leader in the field of regenerative medicine. I will start with an update on the Regenerative Breast Implant Program. This quarter, we continue to advance our preclinical study that includes 200cc commercial-sized breast implants composed of our proprietary Rh-collagen-based bioinks and printed with the Stratasys 3D printer. This study is critical to advancing our technology towards a marketed product and creating significant shareholder value. This most recent preclinical study launched in Q3 using clinical size implants has been designed to assess product performance and safety and is implementing a new and more suitable animal model a refined surgical protocol, and optimized implant design and formulation. Specifically, the implant has been designed to enable controlled degradation kinetics, which means that the implant degrades over time in full synchronization with new tissue ingrowth, allowing for structural stability throughout the tissue regeneration process. Furthermore, the implant now has enhanced durability and its design has been optimized to enable minimally invasive administration of the implant through smaller incisions, as well as providing natural theory. All these improvements significantly contribute to the procedure's efficiency. I'm happy to update today that the study shows good results three months post-implantation. So far, we have seen significant implant vascularization and rapid ingrowth of native tissue. Both are critical factors which enable an effective integration of the implant with the host tissue and support long-lasting regenerative processes. In terms of follow-up, an MRI as well as histopathology serve as the primary tools to follow up on tissue ingrowth as well as implant integrity and degradation over time. This study is intended to mark the completion of the development phase, and we are now one step closer to advancing to human studies. It is also important to note that this data will enhance our position in discussions with potential partners. Our recombinant human collagen technology, which is the backbone of our programs, including the regenerative breast implant, has the same molecular identity as human collagen. As shown here, our collagen has been fully characterized for its molecular, biological, and physical properties, and therefore serves as an ideal scaffolding molecule for tissue regeneration without eliciting immune response. It is considered to be the most characterized collagen in the regenerative medicine market. Our regenerative breast implant product candidate could be revolutionary for both women undergoing aesthetic enhancement as well as cancer patients undergoing breast reconstruction since it has the potential to overcome the challenges of existing breast implants made of silicone saline or autologous fat tissue. Additionally, a breast regenerated from the patient's own tissue may eliminate the need for future procedures or corrections. We know that the global breast implant market is extremely lucrative and estimated at approximately $3 billion, with breast reconstruction and augmentation procedures representing the second most common plastic surgery procedure performed worldwide today. This market also has attractive growth characteristics and is projected to grow to approximately $6.5 billion by 2033. Based on historical safety concerns and worries about future surgical corrections, we believe that the organic demand for natural, newly grown human tissue breast implants could be significant. As we have noted previously, current implant materials can cause immunogenic reactions and have been associated with anaplastic large cell lymphoma, a rare form of cancer. The availability of a regenerative breast implant could be transformational for aesthetic and reconstructive procedures to minimize the adverse events related to currently available implants. Our collaboration with AbbVie continues and it is currently focused on the development of a dermal and soft tissue filler product for the medical aesthetics market. This product candidate offers both wrinkle filling properties as well as the ability to regenerate skin tissue and therefore has its own potential to create a paradigm shift in the aesthetics market. The filler market is valued approximately $5.5 billion and is expected to grow 10% by year. We fully support capitalized path towards clinical testing of our implants. Therefore, we are prioritizing being able to secure non-dilutive cash for the company through forming additional collaboration partnerships. There is a continuous demand for our BioInks and other applications for our recombinant human collagen. Along these lines, we have had additional interest from a wide range of companies that want to gain access to our Rh collagen and are engaged in discussions. We are also streamlining existing operations and being prudent about reducing our annual bear rate. And lastly, during November 10 to 13, COIL Plan showcased at the annual meeting of the International Society for Biofabrication, ISBF. ISBF is a professional society promoting biofabrication research and development for medical applications. During the conference, we presented our technology platform for the mass production of human collagen and biofabrication of innovative regenerative breast implants. Our presentation has gained a wide interest from the audience and opened new collaboration opportunities with academic institutes. That concludes my initial remarks. Now I'll turn the call over to our Deputy CEO and Chief Financial Officer, Eran Rotem, to provide a recap of the financial results. Eran?